Literature DB >> 6617740

Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.

R A Glennon, R Young, J A Rosecrans.   

Abstract

Rats trained to discriminate 1.0 mg/kg of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) from saline in a two-lever operant choice task were administered doses of mescaline, LSD, 5-methoxy-N,N-dimethyltryptamine (5-OMe DMT), quipazine, TFMPP and RU-24969. The DOM-stimulus generalized to the three hallucinogenic agents and to quipazine, but not to the purported serotonin agonists TFMPP or RU-24969. Pretreatment of the animals with the 5-HT2 antagonists ketanserin and pirenperone antagonized the effect produced by DOM. Pirenperone also blocked DOM-stimulus generalization to mescaline, LSD, 5-OMe DMT and quipazine. The results of this study suggest that the discriminative stimulus effects of DOM, the three hallucinogenic agents to which DOM-stimulus generalization occurred, and quipazine, may involve those sub-populations of serotonin receptors that are labeled by tritiated ketanserin (i.e. 5-HT2 sites).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617740     DOI: 10.1016/0014-2999(83)90464-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  38 in total

1.  Central serotonin receptors: effector systems, physiological roles and regulation.

Authors:  P J Conn; E Sanders-Bush
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 2.  The behavioral pharmacology of hallucinogens.

Authors:  William E Fantegrossi; Kevin S Murnane; Chad J Reissig
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

3.  PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors.

Authors:  Atheir I Abbas; Prem N Yadav; Wei-Dong Yao; Margaret I Arbuckle; Seth G N Grant; Marc G Caron; Bryan L Roth
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

4.  Evidence for 5-HT2 receptor mediation in quipazine anorexia.

Authors:  R Shukla; D MacKenzie-Taylor; R H Rech
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Psychedelics and the human receptorome.

Authors:  Thomas S Ray
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

6.  Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice.

Authors:  Mario de la Fuente Revenga; Urjita H Shah; Nima Nassehi; Alaina M Jaster; Prithvi Hemanth; Salvador Sierra; Malgorzata Dukat; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2021-01-05       Impact factor: 4.418

7.  Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.

Authors:  Danuta Marona-Lewicka; Ronald A Thisted; David E Nichols
Journal:  Psychopharmacology (Berl)       Date:  2005-02-19       Impact factor: 4.530

Review 8.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

9.  Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys: antagonism and apparent pA2 analyses.

Authors:  Jun-Xu Li; Kenner C Rice; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2008-12-19       Impact factor: 4.030

Review 10.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.